J&J | JNJ - Interest Expense On Debt


J&J reported $43M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Abbott USD 297M 2M Sep/2026
Amgen USD 653M 94.99B Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Baxter International USD 64M 14M Jun/2026
Bayer EUR 675M 87M Dec/2025
Becton, Dickinson and Co. USD 130M 2M Sep/2026
Biogen USD 72.6M 12.6M Jun/2025
Boston Scientific USD 100M 4M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
CONMED USD 11.14M 3.25M Sep/2026
Cooper Companies USD 21.5M 600K Jun/2026
Dexcom USD 3.1M 100K Sep/2026
Edwards Lifesciences USD 30M 5.9M Jun/2026
Eli Lilly USD 316M 201.3M Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Globus Medical USD 5.53B 39.93M Sep/2026
Insulet USD 12.3M 1.3M Sep/2026
Integra LifeSciences USD 22.96M 33K Sep/2026
Intuitive Surgical USD 19.35B 1.53B Sep/2026
J&J USD 43M 25M Mar/2026
Medtronic USD 186M 10M Jun/2026
Merck USD 525M 46M Jun/2026
Merit Medical Systems USD 7.33M 4.78M Sep/2026
Novartis USD 468M 6M Sep/2026
Pfizer USD 662M 5M Sep/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 222M 65M Sep/2026
Stryker USD 47.25B 683M Sep/2026
Tandem Diabetes Care USD 1.16B 5.29M Sep/2026
Teva Pharmaceutical Industries USD 414M 219M Sep/2026
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026
Zimmer Biomet Holdings USD 23.54B 740.8M Sep/2026
Zoetis USD 62M 1000K Sep/2026